Lichen Sclerosus Maintenance: What to Do Between Flares

Most people think lichen sclerosus management is about surviving flares. The biology tells a different story. What happens between flares is what determines how often they return, how severe they become, and whether the skin eventually stabilizes or remains persistently fragile. The quiet periods are not neutral time. They are when the condition either consolidates or slowly escalates, and the approach taken during those periods shapes the long-term course of the disease more than any individual treatment episode.

Many people fall into one of two patterns after a flare settles. The first is stopping everything as soon as symptoms improve, treating the absence of pain as the absence of disease. The second is remaining in flare-mode indefinitely, continuing aggressive treatment protocols long after the acute phase has resolved. Both approaches keep the underlying system unstable, for different reasons. Maintenance is not passive waiting between crises. It is active stabilization of a tissue that remains immunologically primed even when it feels calm.

What Maintenance Actually Means in Lichen Sclerosus

Maintenance does not mean daily high-potency steroids, constant product layering, or aggressively treating skin that already feels settled. The definition is more precise than that: keeping immune activity below the flare threshold, protecting fragile tissue from daily re-triggering, and preventing the kind of silent escalation that produces a full inflammatory reactivation weeks later with no obvious cause.

Even when symptoms improve substantially, lichen sclerosus does not disappear. The immune signaling quiets, the NF-kB cytokine cascade drops below clinical threshold, and the TGF-beta fibrosis loop slows. But the tissue remains structurally altered, the barrier remains thinner than healthy skin, and the local immune environment remains sensitized. A 507-woman cohort study published in 2015 found that preventive topical corticosteroid regimens significantly improved symptom control and reduced scarring risk compared to treating only during active flares, which underscores that the quiet periods carry real clinical weight. Maintenance exists to hold the line between stability and reactivation.

Why Flares Often Return After Successful Treatment

Most relapses are not treatment failures. They are maintenance failures, and the distinction matters because the solution is different in each case. When a flare is treated effectively, the inflammatory cascade quiets, symptoms resolve, and the skin enters what functions as Phase 4 of the LS cycle: remission and fragile stability. The word fragile is doing real work there. The tissue has not returned to baseline. It has returned to a state that can hold, but only if the conditions that triggered the original flare are not recreated.

The biology behind most relapses involves low-grade immune reactivation through pathways including TNF-alpha and IL-1beta, cytokines that can be re-activated by mechanical stress, barrier disruption, or the gradual accumulation of daily triggers that individually seem insignificant. This is where the two-day delay mechanism becomes important: mechanical micro-injury from something as routine as tight clothing or vigorous wiping does not produce immediate symptoms. The immune activation that follows arrives 12 to 48 hours after the event, which makes it extremely difficult to trace back to its source. By the time the skin becomes symptomatic, the triggering moment feels unrelated, and the relapse seems to arrive without explanation.

Stopping treatment abruptly when symptoms improve removes the low-level suppression that was keeping that reactivation threshold intact. Friction returning too quickly, barrier care being abandoned once things feel better, and the natural relaxation of vigilance that follows relief all contribute to the same outcome. A scoping review of treatment options in vulvar lichen sclerosus found that stopping treatment when symptoms improve reliably leads to relapse, and that long-term low-dose topical corticosteroids combined with emollients represents the current clinical standard. Maintenance interrupts the reactivation process before symptoms become obvious, which is a fundamentally different objective than treating active inflammation.

Steroids During Maintenance: Less, Not None

Between flares, inflammation is usually reduced rather than absent. The NF-kB pathway is quieter but not switched off, and low-grade cytokine activity continues below the clinical detection threshold. This is precisely why the steroid approach during maintenance differs from the approach during an active flare, and why abruptly stopping all corticosteroids often produces the rebound that patients and clinicians mistake for disease progression.

A rational, research-supported pattern involves using clobetasol only during clearly active flares when the inflammatory cascade is fully engaged, stepping down to mometasone when inflammation is moderate and the acute phase is resolving, and transitioning to hydrocortisone during the low-activity maintenance phase when steroid use is still warranted but high potency is no longer appropriate. The comparison study of clobetasol versus mometasone found that moisturizing cream functions as an integral part of this stepped approach, supporting the barrier as potency is reduced. The goal throughout is not daily suppression of a quiet system. It is preventing the silent escalation that occurs when low-grade immune activity is given no counterweight at all.

Structured maintenance steroid use should feel boring and predictable rather than dramatic. The absence of drama is the signal that it is working. Clinical guidelines from multiple centers, including the Mayo Clinic's published treatment framework, support intermittent steroid ointment combined with daily moisturizers as the approach that keeps lichen sclerosus under long-term control. Abruptly stopping all steroids as a response to feeling better is not a conservative choice. It is a setup for the next flare.

Barrier Protection Is the Backbone of Maintenance

Once inflammation is controlled and the acute phase has resolved, mechanical stress becomes the primary driver of reactivation. The skin in the maintenance phase is thinner than healthy tissue, less elastic, and more sensitive to friction than it was before the disease began. This is not simply because of the active inflammation that was just treated. It reflects the structural reality of post-inflammatory tissue: the stratum corneum is depleted of ceramides, collagen architecture has been remodeled by TGF-beta signaling, and the barrier's normal protective function has been compromised.

This is why barrier protection functions as the structural backbone of maintenance rather than an optional add-on. Petrolatum and Vaseline provide strong friction reduction and are among the most researched options for this purpose, with petroleum-based products appearing consistently in clinical recommendations for post-treatment barrier support. Cicalfate tends to be more appropriate when skin feels raw or is recovering from recent irritation, given its reparative properties. Cicaplast B5+ suits daily maintenance in genuinely stable phases. VEA Lipogel, Vitamono EF, and zinc-based barrier products offer neutral protection with minimal inflammatory potential. None of these products treat lichen sclerosus directly. Their function is to prevent the mechanical and environmental conditions that re-trigger it.

The NHS Right Decisions guidance on vulval lichen sclerosus explicitly frames continued emollient use as active stabilization rather than cosmetic comfort, describing ongoing barrier application as directly reducing friction and flare-ups over the long term. The research on moisturizer maintenance by Goldstein and colleagues found that daily moisturizing cream maintained symptom relief and reduced steroid requirements after an initial steroid course, which points to a meaningful and measurable clinical effect from barrier care alone.

Moisture Versus Protection: Why Over-Hydration Backfires

A common mistake during maintenance is treating barrier care as synonymous with hydration, then applying progressively thicker or wetter products in the belief that more moisture equals better skin health. The biology does not support this. Excess moisture in the genital region can increase friction by creating a softened, less resilient surface, trap heat in a way that activates mast cells and contributes to the neuroimmune itch loop, and alter the local microbiome in ways that can introduce a secondary inflammatory trigger into an area that was just stabilizing.

This is why some people report feeling worse despite moisturizing consistently and following general skincare advice carefully. Between flares, thin protective layers typically outperform heavy hydrating formulations. The objective is not to flood the tissue with water or occlusive moisture. The objective is to create a stable, low-friction interface between the skin and its mechanical environment. The skin should feel protected and calm, not damp or sealed. The distinction between protecting and hydrating matters enough that choosing the wrong product category, even from among products generally considered appropriate for lichen sclerosus, can contribute to the barrier damage loop it was intended to prevent.

Friction Control Matters More Than New Products

During maintenance, what touches the skin throughout the day carries more influence over long-term stability than any single product applied once. This is a principle that consistently surprises people who have focused their attention primarily on topical treatments, but it follows directly from the biology. If the two-day delay mechanism means that micro-injury today produces immune activation tomorrow or the day after, then chronic low-level friction from everyday sources generates a constant background of immune stimulation that no maintenance steroid regimen can fully counteract.

The sources of that friction are mundane: underwear fit and waistband pressure, seam texture and synthetic fabrics that hold heat and reduce air circulation, patterns of daily movement and prolonged sitting, and wiping habits that feel normal but impose repeated mechanical stress on tissue that cannot absorb it the way healthy skin can. Even mild friction repeated many times each day can sustain the trigger amplification loop at a level that prevents the system from ever fully settling. Reducing friction sources consistently and deliberately often extends remission more reliably than introducing additional products into a routine that is already doing its core job.

Washing During Maintenance: Keep It Minimal

When inflammation is quiet and the skin is in a stable phase, the approach to cleansing should shift toward the minimal end of the spectrum. Gentle, infrequent, and predictable washing is not a sign of inadequate hygiene. It reflects an accurate understanding of what the tissue can tolerate during this phase. The barrier is still recovering structural integrity, and the surfactants in most cleansers, even gentle ones, strip ceramides and disrupt the acid mantle in ways that are consequential for skin that has reduced capacity to repair quickly.

Over-washing during maintenance frequently destabilizes skin that was just calming down, reactivating the barrier damage loop by depleting the ceramide layer that was slowly reconstituting. The practical signal to watch for is whether washing leaves the skin noticeably tighter, more aware, or sensitive in the minutes or hour afterward. If it does, the cleansing routine is too aggressive for this phase of the condition, regardless of how mild the product is marketed to be. Clean is a sufficient standard during maintenance. Sterile is neither necessary nor achievable, and pursuing it creates more harm than the microbiological benefit justifies.

Early Intervention Beats Flare Protocols

The most effective maintenance strategy is not a perfectly calibrated product routine. It is the ability to recognize early warning signals and respond to them before the inflammatory cascade becomes self-sustaining. Phase 1 of the LS cycle begins with NF-kB activation and the release of TNF-alpha, IL-1beta, and IL-6, and at that early stage the system is still responsive to relatively modest interventions. Once the cascade advances toward Phase 2, with barrier breakdown, erosion, and the barrier damage loop fully engaged, the clinical response required becomes substantially more aggressive and the recovery time substantially longer.

Early signals worth recognizing include mild burning that is not yet accompanied by visible change, increased sensitivity to products that have been tolerated well, and subtle tightness that does not resolve after barrier application. These sensations often settle with improved barrier protection, a temporary return to low-potency steroid use, and a reduction in friction sources, without ever requiring the full clobetasol induction protocol. Waiting until symptoms have fully escalated before intervening almost always means needing stronger treatment for longer, which carries its own consequences for skin integrity and long-term tolerance. The research consistently supports the principle that earlier intervention at lower potency preserves more tissue architecture than delayed intervention at higher potency.

What Maintenance Is Not

Maintenance is not permanent high-potency steroid use. The risks of sustained clobetasol application to already-thin genital tissue are well established, and the goal of steroid tapering is specifically to avoid creating the iatrogenic atrophy that becomes indistinguishable from the disease process itself. Maintenance is also not constant experimentation with new products, a pattern that introduces repeated chemical exposures to a sensitized system and prevents the kind of stable baseline that makes it possible to identify what is actually helping.

Fear-driven routines that escalate treatment in response to every minor sensation misread the biology. The objective during maintenance is stability, and stability has a particular texture: it feels boring, predictable, and uneventful. Skin that generates no notable sensations, that tolerates its routine without drama, and that produces no new findings is skin that is doing well. Chasing perfect sensation, meaning the complete elimination of any awareness of the tissue, sets an unrealistic standard that drives over-treatment and keeps the system in a state of constant adjustment when what it needs is consistent calm.

The Long-Term Payoff of Good Maintenance

The research on long-term outcomes in lichen sclerosus points consistently toward one conclusion: the patients who fare best over years are not those who receive the most aggressive treatment during flares, but those who maintain consistent low-level management between them. The 507-woman cohort study found that preventive topical corticosteroid regimens reduced scarring and carcinoma risk significantly compared to flare-only treatment approaches. The scoping review found that ongoing low-dose topical corticosteroids with emollients reduced relapse frequency and steroid dependence over time. The moisturizer maintenance data found that barrier support alone, after an initial steroid course, sustained symptom relief and reduced the frequency with which stronger treatment became necessary.

What these findings describe collectively is a system that responds to consistency. Fewer flares mean less cumulative inflammatory damage to the tissue architecture. Milder flares, when they do occur, mean shorter recovery times and less potent treatment requirements. Less reliance on high-potency steroids over time means less iatrogenic atrophy and a more resilient starting point for the next maintenance period. Improved skin tolerance, which develops gradually through consistent barrier protection and friction reduction, reflects genuine structural stabilization rather than simply a stretch of good luck. This is where the long-term course of lichen sclerosus is decided, not during isolated treatment episodes, but in the accumulated weight of the choices made during the quiet periods in between.

The Biology of the Quiet Periods

Flares receive attention because they are loud and painful and demand a response. The quiet periods between them feel like the absence of the problem, when in fact they are the period during which the problem is either being resolved or being rebuilt. The five feedback loops that drive lichen sclerosus, the inflammation loop, the barrier damage loop, the neuroimmune itch loop, the fibrosis loop, and the trigger amplification loop, do not switch off because symptoms have quieted. They drop below clinical threshold, but they remain structurally present in tissue that has been remodeled and sensitized.

Maintenance is what keeps those loops below threshold. Doing less, but doing it consistently, is the principle that the research supports and that clinical experience confirms. A modest barrier routine applied without interruption, a steroid step-down protocol that tapers intelligently rather than stopping abruptly, friction sources identified and reduced rather than ignored because they seem trivial: these are the mechanisms through which damage is prevented, routines stabilize, and the future course of the condition is shaped. The quiet periods are where the work is done.

‍

Content sourced from: Lichen Sclerosus Decoded, A New Way to Understand and Manage Lichen Sclerosus. For informational purposes only. This article does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.

Scientific References: Lichen Sclerosus Maintenance Therapy

1. Long-term Management of Adult Vulvar Lichen Sclerosus: 507-woman cohort – preventive TCS regimens improving symptom control, reducing scarring and carcinoma risk vs flare-only treatment
2. Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review – long-term low-dose TCS plus emollients as standard, stopping when symptoms improve leads to relapse
3. Vulvar Lichen Sclerosus: Clinical Aspects and Guidelines to Manage – most patients requiring some level of maintenance after ultrapotent steroid induction, relapse common without ongoing management
4. Diagnosis and Treatment of Lichen Sclerosus: An Update – chronic relapsing disease, reduced-frequency long-term maintenance, risks of undertreatment and excessive continuous high-potency use
5. Vulvar Lichen Sclerosus: Effect of Maintenance Treatment with a Moisturizer – daily moisturizing cream maintaining symptom relief and reducing steroid use after short steroid course
6. Vulvar Lichen Sclerosus: Comparison of Clobetasol vs Mometasone – moisturizing cream as integral part of treatment, stepping down from clobetasol with barrier support
7. Topical Corticosteroids Still the First Choice – clobetasol and mometasone effective, ongoing lower-intensity regimens, correct tapering and maintenance mattering more than stopping when better
8. Topical Hormones and alternatives in Lichen Sclerosus – regular emollient and barrier application integral after initial corticosteroid treatment, petroleum-based products commonly recommended
9. Vulval Lichen Sclerosus – NHS Right Decisions – LS long-term, ongoing treatment needed, continued emollients reducing friction and flare-ups, maintenance as active stabilization
10. Mayo Clinic: Lichen Sclerosus Diagnosis and Treatment – symptoms returning if treatment stopped, intermittent steroid ointment plus daily moisturizers keeping condition under control